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Enhancement of sensitivity ofhuman lung adenocarcinoma cells to growth-
inhibitory activity of interferon ac by differentiation-inducing agents
I Goto"2, Y Yamamoto-Yamaguchi' and Y Honmal
'Department of Chemotherapy, Research Institute and 2Pulmonary Medicine Clinic, Hospital, Saitama Cancer Center, Ina, Kita-
adachi, Saitama 362, Japan.
Summary A low concentration of differentiation inducers such as dimethylsulphoxide (DMSO), sodium
butyrate, hexamethylene bisacetamide and sodium phenylacetate greatly enhanced the antiproliferative effect in
vitro and in vivo of interferon a (IFN-a) to several human lung adenocarcinoma cells. The agents induced
morphological changes in the adenocarcinoma cells and the agents together with IFN-a-induced alkaline
phosphatase activity, which is a typical marker of type II pneumocyte maturation. To understand the
mechanism of the DMSO-enhanced interferon sensitivity, we examined the effect of DMSO on high-affinity
IFN-a receptor and interferon-stimulated promoter-binding factors. The lung adenocarcinoma cells were not
impaired in IFN-a receptor and interferon-stimulated gene transactivation factor 3 (ISGF-3). Our data suggest
that the enhancement of interferon sensitivity in the lung adenocarcinoma cells acts downstream of the
activation of ISGF-3.
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Lung cancer survival remains poor, with approximately 13% a
5 year survival in 1993 (Ginsberg et al., 1993). The most
active drugs so far have been cis-platinum (II) diamine
dichloride (CDDP) (Loether and Einhorn, 1984), vindesine
(Klastersky et al., 1983), vinblastin, mitomycin C and
ifosphamide (Worrall, 1982) in the chemotherapy of non-
small-cell lung cancer. The overall response rate is in the
range 20-30% with 3-5% complete responses (Donnadieu
et al., 1991). The current treatment results from non-small-
cell lung cancer clearly call for improved therapy.
The degree of differentiation is an important prognostic
factor in many tumours. Induction ofdifferentiation is closely
linked to loss of tumorigenicity, and differentiation inducers
can block the phenotypic expression of malignant cells. The
use of all-trans retinoic acid in the treatment of patients with
acute promyelocytic leukaemia has shown that differentiation
therapy can lead to a predictable clinical remission (Huang et
al., 1988; Degos, 1990; Ohno et al., 1993). However,
administration of differentiation inducer alone in experi-
mental therapy of solid tumours has produced only low
remission rates. Furthermore, differentiation induction of
solid tumours is not always an irreversible process. These b
findings call for other strategies, such as combination of
differentiation induction with chemotherapy, radiotherapy
and/or immunotherapy. Induction ofdifferentiation alters the
properties of leukaemia and embryonal carcinoma cells, such
as sensitivities to chemotherapeutic drugs (Okabe-Kado et al.,
1986; Honma et al., 1991; Okabe-Kado et al., 1991;
Guchelaar et al., 1993). We previously reported that
treatment with haemin, an inducer of erythroid differentia-
tion, greatly increased the sensitivity of human myeloid
leukaemia K562 cells to 1-fl-D-arabinofuranosyl cytosine
(Honma et al., 1991; Okabe-Kado et al., 1986), and that
erythroid differentiation factor (activin A) enhanced the
sensitivity of multidrug-resistant leukaemia cells to vincris-
tine, actinomycin D and doxorubicin (Okabe-Kado et al.,
1991).
In order to find a rational combination of differentiation
and chemotherapy on lung carcinoma, we characterise in this
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study the effect of differentiation-inducing agents on
sensitivity of lung carcinoma cells to several anti-cancer
drugs including interferon cx (IFN-cx).
Materials and methods
Chemicals
Human natural IFN-ai (Sumiferon) was kindly gifted by
Sumitomo Seiyaku, Tokyo, Japan. Sodium butyrate and
dimethyl sulphoxide (DMSO) were obtained from Wako Pure
Chemicals, Osaka, Japan. Hexamethylene bisacetamide
(HMBA), doxorubicin, 5-fluorouracil (5-FU), etoposide
(VP-16) and CDDP were supplied from Sigma, St Louis,
MO, USA. The reagents except DMSO were dissolved in
phosphate-buffered saline (PBS). The stock solutions were
prepared as 100-fold concentrates.
Cells and cell culture
All human lung carcinoma cell lines used in the present
experiments were maintained in RPMI-1640 medium (Gibco
BRL, Grand Island, NY, USA) supplemented with 10%
heat-inactivated fetal bovine serum (JRH Bioscience, Lenexa,
KS, USA) and non-essential amino acids of Eagle's minimum
essential medium (EMEM) (Gibco BRL) at 37°C in a
humidified atmoshphere of 5% carbon dioxide in air. We
used 11 lung cancer cell lines (five adenocarcinoma, two
small-cell carcinoma, two large cell carcinoma, and two
squamous cell carcinoma) in the present study. The cell lines
PC9 (Sakiyama et al., 1986), PC14 (Azuma et al., 1995), PC7
(Ohtani et al., 1976), ABC-1 (Hiraki et al., 1982) and A549
(Giard et al., 1972) derived from adenocarcinoma, the cell
lines EBC-1 (Hiraki et al., 1982) and LK2 (Yoshioka, 1989)
from squamous cell carcinoma, the cell lines Lu65 and Lu99
(Yamada et al., 1985) from large-cell carcinoma, and the cell
lines Lu135 (Terasaki et al., 1986) and H69 (Kasahara et al.,
1991) from small-cell carcinoma, have been described
previously. All the cell lines were kindly supplied from the
Japanese Cancer Research Resources Bank (Tokyo, Japan).
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Assay of cell growth
The cells were seeded at a concentration of 105 ml-' in a
multidish (Nunc, Roskilde, Denmark). After culture with or
without test compounds for the indicated times, viable cells
were examined by the modified MTT assay (Goto et al.,
1994). Briefly, 100 pl of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) solution (5 mg ml-' in
PBS) was added to each well. After incubation with MTT for
4 h, the cells were centrifuged at 1000 g for 10 min. The
precipitates were dissolved in 1 ml of DMSO and their
absorptions at 560 nm were determined.
Assay ofalkaline phosphatase activity
Alkaline phosphatase activity is a marker for maturation of
the type II pneumocytes and is not expressed in other
alveolar cells (Edelson et al., 1988; McCormick et al., 1995).
Cells were washed twice with cold PBS, resuspended to a cell
density of 107 cells ml-1 of cold distilled water and sonicated
for 10 s. The reaction mixture contained 50 mM glycine-
sodium hydroxide (pH 10.5) and 0.5 mm magnesium
chloride, 4.2 mM p-nitrophenyl phosphate, and the cell
lysate in a total volume of 0.4 ml. The incubation was
allowed to proceed for 60 min at 37°C and then the reaction
was stopped by the addition of 1 ml of 0.1 M sodium
hydroxide. The absorbance ofp-nitrophenol was determined
at 410 nm for calculation of the enzyme activity (Koyama
and Ono, 1976).
Transplantation of lung carcinoma cells into nude mice
Seven-week-old female athymic nude mice with a BALB/c
genetic background were supplied by CLEA Japan (Tokyo,
Japan). They were housed under specific pathogen-free
conditions in clean racks (Sanki Kogyo, Tokyo, Japan).
Mice were inoculated s.c. with 106 PC14 cells. Mice were
given i.p. injections every other day of 2 x 104 IU of IFN-a
and/or s.c. injections every day, of 0.2 ml of PBS including
40 ,l of DMSO, with the first injection being given 24 h after
PC9 cells
Figure 2 Induction of alkaline phosphatase activity of PC9 and PC14 cells by 0.4mM sodium butyrate or 1% DMSO in the
presence or absence of 1000 IUml-1 IFN-x. Cells were treated for 5 days, and then the enzyme activity was assayed. Values are
means+s.d. of four determinations.
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inoculation of tumour cells. Tumour size was measured
(length and width) with venier calipers every day. At day 16,
sizes of the resected tumours were directly measured before
histological examination. Statistical analysis was performed
using Student's t-test.
Cellular binding assay of IFN-a
Pure recombinant human IFN-ca (Pepro Tech, Rocky Hill, NJ,
USA) was labelled with 125I sodium iodide by a chloramine T
method to a specific activity of 1-2 MBq mg-' without loss of
biological activity. Aliquots of200 !l ofcell suspension (5 x 106
cells ml-') were incubated at room temperature for 2 h with
[I251]IFN-oeatdifferentconcentrationsrangingfrom0.1 to4 nM.
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Non-specific binding was determined in parallel experiments in
thepresenceof100-foldexcessofunlabelledIFN-a.Thenumber
of binding sites per cell and their dissociation constants were
determined from Scatchard analysis (Martyre and Wietzerbin,
1994).
Gel mobility shift assay
The synthetic double-stranded oligonucleotides corresponding
to the sequence -113 to -74 of human 2-5 (A)-synthetase
gene (Rutherford et al., 1988) containing the interferon-
stimulated response element (ISRE) region was synthesised in
a DNA synthesiser (Applied Biosystem model 392). The
sequences of the oligonucleotides were 5'-gCTCCTCCCT-
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Figure 3 Induction of sensitivity to IFN-a by treatment with DMSO in human lung cancer cells. Cells were treated with various
concentrations of IFN-a in the presence of 0 (0), 0.25 (O), 0.5 (-) and 1% (C]) DMSO for 4 days. Values are means of four
determinations.
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rTCTGAGGAAACGAAACCAACAGCAGTCCAAG-3' and
3'-GAGGAGGGAAGACTCCTTTGCTTTGGTTGTCGT -
CAGGTTCg-5'. An oligonucleotide, g, was added to the 5'
end of the synthetic nucleotides for the labelling reaction.
Oligonucleotides were gel purified, annealed and labelled by
Klenow fragment using [_-32P]dCTP. The labelled double-
stranded oligonucleotide was used as probe in gel mobility
shift assay. Nuclear extracts were prepared by a modification
(Xu et al., 1994) of the procedure of Dignam et al. (1983).
Nuclear extracts (10 ig of protein) were incubated in 15 1ul of
total reaction mixture containing 5 mM Tris-HCl (pH 7.5),
50 mm sodium chloride, 1 mM magnesium chloride, 0.5 mM
dithiothreitol, 0.5 mM EDTA, 4% glycerol, 0.005% NP40
and 1 pg of poly (dI-dC) and the 32P-labelled probe (5 fmol)
for 20 min at room temperature (Xu et al., 1994). For
competition and mobility shift interference assays, nuclear
extracts were preincubated in binding buffer with either an
excess ofunlabelled probe for 10 min at room temperature or
0.75,g of anti-interferon-stimulated gene transactivation
factor (ISGF)-3 monoclonal antibody (Funakoshi Pharma-
ceutical Co., Tokyo, Japan) for 30 min at 4°C, respectively.
The samples were loaded onto native 4% polyacrylamide gel
and electrophoresis was carried out in 0.5 x TBE (45 mM
Tris-borate, 45 mm boric acid, 1 mM EDTA) at 170 V. The
gel was dried and then subjected to autoradiography using a
bioimage analyser (Fujix BAS 2000, Tokyo, Japan).
Results
Effect ofdifferentiation-inducing agents on sensitivity to anti-
cancer drugs of lung carcinoma cell lines
For measurement of the effects of anti-cancer drugs on
growth of lung cacrinoma cells, the number of viable cells
was determined by the MTT assay after 5 days, exposure to
various concentrations of drugs. The growth-inhibiting
effects of drugs were examined by determining the
concentrations of drugs required to reduce the cell number
to one-half that of untreated cells (IC50). DMSO, HMBA,
sodium butyrate and phenylacetate are well known as
differentiation inducers of human myeloid leukaemia cells
(Reuben et al., 1976; Hozumi, 1983; Samid et al., 1992).
These agents were not toxic to the lung carcinoma cell lines
when used in a range of concentrations that were effective in
inducing differentiation of human myeloid leukaemia cells.
IC50s of DMSO, HMBA, sodium butyrate and phenylacetate
in PC9 cells was 465, 4.2, 2.3, and 32 mM respectively.
Treatment with more than 128 mM (1%, v/v) DMSO
induced morphological changes in lung adenocarcinoma
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PC9 cells; there were spindle-shaped and round cells in
untreated culture of PC9 cells (Figure la), while DMSO-
treated PC9 cells adhered closely to each other and were
cuboidal and polygonal (Figure lb). Similar morphological
changes in PC9 cells were also observed when treated with
sodium butyrate or HMBA (data not shown). As alkaline
phosphatase activity is a marker for maturation of type II
pneumocytes (Edelson et al., 1988; McCormick et al., 1995),
we measured the effect of several differentiation inducers on
alkaline phosphatase activity of PC9 and PC14 cells. Sodium
butyrate and DMSO significantly induced alkaline phospha-
tase activity of PC14 cells, but PC9 cells were less sensitive
to DMSO in induction of alkaline phosphatase activity
(Figure 2). IFN-a did not essentially induce enzyme activity
in PC9 cells either, but the combined treatment with DMSO
and IFN-ax greatly induced alkaline phosphatase activity in
the cells (Figure 2).
Next, we examined effects of the differentiation inducers
on the sensitivity to anti-cancer drugs. Treatment with
DMSO did not essentially affect sensitivity of the human
lung carcinoma cells to CDDP, VP-16, doxorubicin or 5-FU
(data not shown). Similar results were obtained when the cells
were treated with butyrate, HMBA or phenylacetate.
However, the sensitivity to IFN-a of adenocarcinoma PC9
cells was greatly enhanced by treatment with a low
concentration of DMSO and the enhancing effect of DMSO
was dose-dependent (Figure 3). Growth of PC9 cells was not
inhibited by treatment with a high concentration of IFN-ct
alone (IC50>6.0x l04 IU ml-%), while growth of 1%
(128 mM) DMSO-treated PC9 cells was effectively inhibited
by IFN-a (IC50 =3.0 x 103 IU ml-'). In the case of Lu65 cells,
IC50s of IFN-a alone and IFN-a plus DMSO were 2.4 x 104
and 1.4x 102 IU ml-' respectively, indicating that DMSO
enhances 170 times the sensitivity to IFN-a (Table I). The
other lung carcinoma cell lines, PC14, Lu65, Lu99 and
Lu135, were also sensitive to the combined treatment with
DMSO and IFN-a, but not to IFN-a alone. With respect to
growth inhibition, lung adenocarcinoma ABC-1 and PC7
cells were highly sensitive to IFN-a alone, whereas H69 cells
were resistant to even the combined treatment with DMSO
and IFN-a (Table I). Similar results were obtained when PC9
cells were treated with sodium butyrate, phenylacetate or
HMBA instead of DMSO (Figure 4). The treatment with
IFN-a in the presence of DMSO or butyrate was effective in
inhibiting growth ofPC9, PC14, Lu65, Lu99 and Lu135 cells,
but HMBA and phenyl acetate were less effective in Lu65
(Figure 4) and Lu135 cells (data not shown). In Lu99 cells,
the sensitising effect of DMSO was relatively weak (Figure 3
and Table I), but butyrate and phenyl acetate were the most
Table I Potentiation of the growth-inhibitory activity of IFN-a in human lung carcinoma cells by DMSO
Growth inhibition (IC50 x 102IUmrl)a b
Cell line -DMSO +DMSO Ratio
Adenocarcinoma
PC9 >600 29.8+3.3 >20
PC14 110+12 4.5+0.2 24.4
PC7 23.3+3.1 8.3+0.9 2.8
ABC-1 7.8+1.2 1.9+0.1 4.1
A549 >600 67.3+6.2 >9
Squamous cell carcinoma
EBC-1 45.2+7.1 19.6+2.4 2.3
LK2 162+13 34.2+8.5 4.7
Large-cell carcinoma
Lu65 242+ 19 1.4+0.1 170
Lu99 >600 59.1+3.8 >10
Small-cell carcinoma
Lu135 >600 37.5+3.3 > 16
H69 > 600 560+24 >1
aCells were cultured with various concentrations ofIFN-ac in the presence or absence of 1% DMSO for 4
days. b IC50 in culture without DMSO/IC50 in culture with DMSO.Enhancement of sensitivit to interferon %O Goto et al
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potent sensitisers among the differentiation-inducing agents
tested (Figure 4), suggesting that the enhancement by
differentiation inducers varies from different carcinoma cells.
The effect of the time addition of DMSO or IFN-a on the
growth inhibition was examined. Figure 5 shows that 4 day
pretreatment with IFN-a significantly affects the growth-
inhibitory activity of DMSO plus IFN-ax on treatment for the
last 3 days, suggesting that delayed addition of DMSO is
effective. On the contrary, the delayed addition of IFN-a was
not so effective in growth inhibition. These results suggest
that continuous treatment with IFN-a is essential to evoke
the synergistic effect with DMSO and IFN-a.
The effect of continuous treatment with 1% DMSO and
600 IU ml-' IFN-a added simultaneously on proliferation of
PC9 cells was examined for 12 days. The cell density was kept
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at 2-6 x I05 ml-' to maintain growing phase, and the
cumulative cell number was calculated from the counts and
the dilution used when feeding the culture. Continuous
treatment with 1% DMSO or 600 IU ml-' IFN-a only
slightly inhibited growth of PC9 cells, but combined
treatment with DMSO and IFN-a caused significant growth
inhibition, suggesting that the combined treatment has
therapeutic value on chemotherapy of some lung cancers.
Effect ofDMSO andIFN-a on in vivo growth ofPCJ4 cells as
xenografts
The in vitro studies described above suggested that combined
treatment with DMSO and IFN-a should be more effective
therapeutically than treatment with DMSO or IFN-a alone.
o 1o1 102 103 lo4
IFN-a (IU ml-,)
Figure 4 Effect of various compounds on sensitivity to IFN-a. Cells were treated with various concentrations of IFN-a in the
absence (A) or presence of 1% DMSO (*), 5mM HMBA (-), 0.5mm sodium butyrate (0) or 3.75mM sodium phenylacetate (El)
for 4 days. Values are means of four determinations.
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The combined treatment significantly inhibited the growth of
PC14 cells as xenografts (Figure 6). At day 16 after
inoculation of tumour cells, the mean tumour sizes of
untreated, DMSO-,IFN-a- and DMSO plus IFN-a-treated
mice were 42.8+22.8, 15.6+22.3, 29.2+19.2 and
6.2+4.8 mm2 (+s.d.) respectively. These results indicate
that the combination treatment with DMSO and IFN-a is
more effective therapeutically than IFN-a or DMSO alone,
and anti-tumour effect of the combined treatment was
statistically significant (P<0.01). The combined treatment
was also effective in xenografts of PC9 cells (data not shown).
Histological examination revealed that central necrosis was
observed in the DMSO+IFN-a-treated tumour (Figure 7b),
whereas the viable cells were evident all over the control
tissues (Figure 7a). Observations of the gross morphology of
the tumours excised after treatment showed not only a
significant difference in size but also a marked reduction in
blood supply, judging by the whiter appearance of the
tumour.
0 101 lo, 103 104 105
IFN-a (IU ml-1)
Figure 5 Effect of pretreatment of DMSO or IFN-a on growth
inhibition of PC9 cells induced by short-term treatment with
DMSO plus IFN-ac. Cells were treated with various concentra-
tions of IFN-a for 4 days, and then cultured with (0) or without
(A) 1% DMSO in the presence of various concentrations of
IFN-a for 3 days. Cells pretreated with 1% DMSO for 4 days
were cultured with various concentrations of IFN-a in the
presence of 1% DMSO for 3 days (*). (U) Cells treated with
IFN-ca plus 1% DMSO for 7 days.
b
Time (days)
Figure 6 Effect of DMSO and IFN-oa on growth of PC14 cells as
xenografts. Mice received daily s.c. injections on 40 jl of DMSO
(A, *) and i.p. injections of 2 x 104IU IFN-a every other day
(0, *). The difference at day 16 between untreated (A) and
DMSO plus IFN-a-treated (*) is significant at P<0.01 (n = 5).
Figure 7 Histology of xenografts. Tumours were excised at 16
days after tumour inoculation, fixed and stained with haematox-
ylin-eosin. (a) Untreated. (b) DMSO +IFN-ac-treated. Original
magnification x 300.
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Effect of DMSO on cellular IFN-cc binding of lung carcinoma
cells
A trivial explanation of the IFN-ac resistance of the lung
cancer cells would be the possible absence of IFN receptors.
The presence of the IFN-oc receptor was determined by the
binding of ['25I]IFN-a to several pulmonary carcinoma cells.
Specific binding in PC9 cells approached saturation at 3.7 nM
IFN-a and Scatchard analysis gave a linear plot, suggesting
the presence of a single high-affinity binding site with
7870+450 receptors/cell and a dissociation constant (Kd) of
42 pM. Scatchard analysis of IFN-ax binding data revealed
that the lung carcinoma cells tested expressed similar
numbers (3000 -10 000 receptors/cell) of high affinity (Kd,
20-100 pM) cell-surface receptor for IFN-cx. Treatment with
DMSO did not essentially affect the high-affinity receptors in
PC9 cells (data not shown).
IFN-oc signalling system in PC9 cells
Some human malignant cell lines are resistant to antiproli-
ferative activity of IFN-ax even though they have normal
numbers of high-affinity IFN-cc receptors. These IFN-
resistant lines are defective in the activation of a promoter-
binding factor (ISGF-3), an early event in the IFN-ac response
(Xu et al., 1994; Kessler et al., 1988). Then we examined the
activation of ISGF-3, which is involved in the activation of
IFN-oc-stimulated genes, in DMSO-treated PC9 cells. PC9
cells were cultured with 1000 IU ml-' IFN-a and 1% DMSO
for 2.5 h, and nuclear extracts were prepared and used for the
gel shift mobility assay of ISGF-3 (Figure 8). Nuclear
extracts that were preincubated with anti-ISGF-3 antibody
showed super-shift moving (Figure 8a, lane 2) and addition
of an excess of unlabelled probe eliminated the band of
ISFG-3 complex (Figure 8a, lane 3). Addition of unlabelled
non-specific DNA competitor (AP-1) had no effect (data not
shown). These results indicate that the binding reaction is
specific to ISGF-3. Next, we treated with 0.5-2% DMSO for
2.5-48 h and examined the effect of DMSO on ISGF-3
binding activity in PC9 cells. Figure 8b shows that ISGF-3
activity in PC9 cells is not essentially affected by DMSO,
suggesting that the ISGF signalling system is effective in
untreated PC9 cells.
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Discussion
IFNs exert anti-tumour activity in several tumours, including
melanoma, renal cell carcinoma and haematological malig-
nancies. However, IFN-a has not been effective as systemic
therapy for advanced non-small-cell lung carcinomas
(Agarwala and Kirkwood, 1994). The impressive effects of
IFN-oc have been in the management of recurrent malignant
pleural effusion, with clinical and pathological improvement.
Even in the case of melanoma, tumours from different
patients vary greatly in their sensitivity to IFN therapy, with
some being more or less susceptible and others being
completely resistant. The reason behind the variation in
IFN sensitivity is not known.
A common sequence motif ISRE has been identified in the
5' regulatory region of ISGs. Binding of IFN molecules to
their receptor triggers the assembly of a cytoplasmic protein
complex and its translocation to the nucleus, where the
activated complex can promote transcription by binding to
ISREs (Levy et al., 1988, 1989; Dale et al., 1989). Only one of
the three well-characterised ISRE-binding factors, ISGF-3,
seems to be directly responsible for the transcriptional
activation of ISGs (Levy et al., 1989). A lack of response
towards IFN-a has been attributed to an impaired activation
of transcription factor ISGF-3 in the case of IFN-resistant
lymphocytic leukaemia cells (Kessler et al., 1988; Xu et al.,
1994). However, as revealed by gel mobility shift assays,
DMSO-treated (IFN-a-sensitive) and untreated (IFN-ac-
resistant) PC9 cells exhibited a nearly identical pattern of
IFN-stimulated response element binding proteins. Activation
of the factor ISGF-3, which has previously been shown to be
required and sufficient for transcriptional activation of IFN-
induced genes, was not impaired in some human lung cancer
cells. Our present data suggest that the IFN resistance and its
restoration by differentiation-inducing agents in some lung
carcinoma cells acts downstream of the activation of ISGF-3.
Enhancement by DMSO of IFN sensitivity in lung cancer
cells was unlikely to be attributed to direct interaction of
DMSO and IFN-ac as the enhancement was also observed
when the cells were treated with the other differentiation
inducers ofmyeloid leukaemia cells, such as butyrate, HMBA
and phenylacetate. These compounds also induced morpho-
logical changes in PC9 and the other lung carcinoma cells,
b
None IFN100 IFN1000 DMSO DMSO+
IFN100
UMbU +
IFNIOOO
Figure 8 Gel shift mobility assay with nuclear extracts of PC9 cells. PC9 cells were cultured with 10OlUml-' IFN-a and 1%
DMSO for 2.5h and nuclear extracts were prepared for the gel shift mobility assay. (a) Nuclear extracts were preincubated with
(lane 2) or without (lane 1) anti-ISGF-3 antibody for 30min at 4°C before the binding reaction was carried out. To examine the
specific binding, 200-fold excess of unlabelled probe was added before the binding assay of ISFG-3 complex (lane 3). Two other
experiments gave similar results. (b) Nuclear extracts from PC9 cells cultured with or without IFN-a (100 or 100OUml-1) in the
presence or absence of 1% DMSO for 2.5h were prepared and used for the gel shift mobility assay. Amounts of ISGF-3 were
quantified using a bioimaging analyser. Values are means+s.d. from three separate experiments.
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although the effect varied for different cell lines. These results
suggest that induction of morphological changes is closely
associated with the sensitisation of PC9 cells to IFN-ac.
However, the precise mechanism of the sensitisation by
DMSO remains undefined. On the other hand, it should be
considered a possibility that IFN-a potentiates the growth-
inhibitory effect of DMSO, as well as sensitisation of IFN-oa
by DMSO. However, the mechanism of DMSO action
remains obscure.
Treatment with DMSO and IFN-cx induced morphological
changes and alkaline phosphatase activity of adenocarcinoma
PC9 and PC14 cells. However, administration of DMSO and
IFN-a did not significantly induce morphological differentia-
tion in xenografts of PC14 cells, suggesting that the anti-
tumour effect of DMSO and IFN-a was not associated with
induction of differentiation in vivo. Further work is required
to understand the anti-tumour effect in vivo of DMSO and
IFN-a.
Retinoic acid is a potent inducer ofmyeloid leukaemia and
the only agent that is clinically used in differentiation therapy
of acute leukaemia (Degos, 1990; Ohno et al., 1993).
Lippman et al. (1992a,b) demonstrated that the combination
of 13-cis-retinoic acid and IFN-a was highly active in the
treatment of patients with advanced squamous cell carcino-
mas of skin and uterine cervix, although the combination
treatment was virtually inactive in patients with advanced
non-small-cell lung cancer (Arnold et al., 1994). Retinoic acid
did not essentially affect the sensitivity of lung cancer cells to
IFN-a in our experiments (data not shown).
DMSO, an industrial solvent, caused partial or total
disappearance of experimentally induced amyloid deposits in
mice (Hanai et al., 1979), and therapeutic trials on patients
with amyloidosis indicated that prolonged treatment with
DMSO may be effective in certain types of systemic
amyloidosis (Isobe et al., 1976; Iwasaki et al., 1994). DMSO
treatment induced a dramatic reduction in pulmonary
infiltration in a patient with IgG multiple myeloma and no
serious side-effect of DMSO was encountered (Iwasaki et al.,
1994). Therapy of HMBA, another polar compound that is
more potent than DMSO in inducing differentiation of
murine erythroleukaemia cells (Reuben et al., 1976), had
some success in clinical trials against certain cancers (Young
et al., 1988). These results suggest that DMSO and HMBA in
combination with IFN-a are useful in treatment with some
lung cancer patients. However, DMSO and HMBA are not
ideal drug prospects. From the extensive structure-activity
relations developed in testing many compounds, it seem likely
that we obtain more useful sensitising compounds in
treatment with IFN-cx of lung cancer patients. This is a
promising approach to lung cancer therapy, potentially
without many of the disadvantages of cytotoxic agents.
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